<!DOCTYPE html>
<html lang="zh-Hant">
  <head>
    <meta charset="UTF-8" />
    <style>
      body {
        font-family: 'Microsoft JhengHei', sans-serif;
      }
      table {
        border-collapse: collapse;
        width: 100%;
        margin: 20px 0;
      }
      th,
      td {
        border: 2px solid #4a86e8;
        padding: 12px;
        text-align: left;
      }
      th {
        background-color: #c9daf8;
        font-weight: bold;
      }
      .section-title {
        background-color: #6d9eeb;
        color: white;
        padding: 10px;
      }
      .reference {
        background-color: #e6b8af;
        padding: 15px;
        border-left: 4px solid #cc4125;
      }
      .warning {
        color: #cc0000;
        font-weight: bold;
      }
    </style>
  </head>
  <body>
    <h1>Nivolumab + Ipilimumab 治療分析報告</h1>

    <!-- 藥物基礎資訊 -->
    <div class="section-title">藥物基礎資訊</div>
    <table>
      <tr>
        <th>項目</th>
        <th>Nivolumab (OPDIVO®)</th>
        <th>Ipilimumab (YERVOY®)</th>
      </tr>
      <tr>
        <td>香港參考價格</td>
        <td>100mg/10ml: ~HK$18,000<br />240mg/24ml: ~HK$38,000</td>
        <td>50mg/10ml: ~HK$28,000<br />200mg/40ml: ~HK$98,000</td>
      </tr>
      <tr>
        <td>作用機制</td>
        <td>PD-1抑制劑<br />解除T細胞抑制</td>
        <td>CTLA-4抑制劑<br />激活初始T細胞</td>
      </tr>
      <tr>
        <td>適應症</td>
        <td>MSI-H/dMMR實體瘤<br />黑色素瘤等</td>
        <td>晚期黑色素瘤<br />腎細胞癌等</td>
      </tr>
      <tr>
        <td>優點</td>
        <td>• MSI-H腫瘤客觀緩解率達60%<br />• 持久性反應</td>
        <td>• 協同增強免疫反應<br />• 提高完全緩解率</td>
      </tr>
      <tr>
        <td>缺點</td>
        <td>• 免疫相關不良事件<br />• 單藥有效率較低</td>
        <td>• 3-4級不良事件達55%<br />• 肝毒性風險高</td>
      </tr>
    </table>

    <!-- 治療方案分析 -->
    <div class="section-title">治療方案分析</div>
    <table>
      <tr>
        <th>時間</th>
        <th>方案</th>
        <th>關鍵發現</th>
        <th>風險評估</th>
      </tr>
      <tr>
        <td>2022-2023<br />(歷史治療)</td>
        <td>Nivo 140mg + Ipi 50mg × 5週期<br />→ Ipi 50mg × 8週期</td>
        <td class="warning">• 非標準劑量方案<br />• Ipilimumab單藥缺乏證據</td>
        <td>累積毒性風險增加</td>
      </tr>
      <tr>
        <td>2025-06-13<br />(新計劃)</td>
        <td>Nivo 200mg + Ipi 50mg × 4週期</td>
        <td>• 符合CheckMate 040標準劑量<br />• MSI-H狀態仍存在</td>
        <td class="warning">再挑戰免疫毒性風險增加</td>
      </tr>
    </table>

    <!-- 基因突變分析 -->
    <div class="section-title">基因突變分析</div>
    <table>
      <tr>
        <th>突變基因</th>
        <th>2022檢測</th>
        <th>2025檢測</th>
        <th>臨床意義</th>
      </tr>
      <tr>
        <td>MSI相關</td>
        <td>MLH1 T237fs*2</td>
        <td>MLH1 T237fs*2</td>
        <td>MSI-H狀態持續</td>
      </tr>
      <tr>
        <td>免疫逃逸</td>
        <td>B2M S16fs</td>
        <td>B2M S16fs + L15fs</td>
        <td class="warning">可能降低治療反應</td>
      </tr>
      <tr>
        <td>治療抵抗</td>
        <td>STK11 L282fs*3</td>
        <td>STK11 L282fs*3</td>
        <td class="warning">免疫治療抵抗風險</td>
      </tr>
      <tr>
        <td>新突變</td>
        <td>-</td>
        <td>MAP2K1 K57T<br />RNF43雙突變</td>
        <td>可能影響靶向治療選擇</td>
      </tr>
    </table>

    <!-- 副作用管理 -->
    <div class="section-title">副作用分級管理</div>
    <table>
      <tr>
        <th>器官系統</th>
        <th>1-2級處理</th>
        <th>3-4級處理</th>
        <th>發生率(O+Y)</th>
      </tr>
      <tr>
        <td>胃腸道</td>
        <td>類固醇(口服)<br />電解質監測</td>
        <td>靜脈類固醇<br />英夫利昔單抗</td>
        <td>35-44%</td>
      </tr>
      <tr>
        <td>肝臟</td>
        <td>ALT/AST監測<br />每週2次</td>
        <td>靜脈甲基強龍<br />永久停藥</td>
        <td>20-30%</td>
      </tr>
      <tr>
        <td>內分泌</td>
        <td>甲狀腺功能檢查<br />激素替代</td>
        <td>應激劑量類固醇<br />專科會診</td>
        <td>15-25%</td>
      </tr>
      <tr>
        <td>皮膚</td>
        <td>外用類固醇<br />抗組胺藥</td>
        <td>全身類固醇<br />暫停治療</td>
        <td>25-35%</td>
      </tr>
    </table>

    <!-- 預後評估 -->
    <div class="section-title">預後評估</div>
    <table>
      <tr>
        <th>正面因素</th>
        <th>負面因素</th>
        <th>預測指標</th>
      </tr>
      <tr>
        <td>• MSI-H持續存在<br />• TMB=56 (極高)<br />• 無KRAS突變</td>
        <td>• PD-L1=0<br />• B2M雙突變<br />• STK11突變<br />• 既往治療進展</td>
        <td>• 12個月生存率: 48-62%<br />• 客觀緩解率: 35-45%<br />• 中位PFS: 5.8-7.2月</td>
      </tr>
    </table>

    <!-- 常見謬誤與改正 -->
    <div class="section-title">常見謬誤與改正</div>
    <table>
      <tr>
        <th>謬誤</th>
        <th>科學證據</th>
        <th>改正方案</th>
      </tr>
      <tr>
        <td>"PD-L1陰性不應使用免疫治療"</td>
        <td>MSI-H患者即使PD-L1陰性仍可獲益<br />(PMID: 30207593)</td>
        <td>優先參考MSI/TMB狀態</td>
      </tr>
      <tr>
        <td>"Ipilimumab單藥維持有效"</td>
        <td>CTLA-4抑制劑單藥無維持證據<br />(NCCN指南v2.2025)</td>
        <td>標準方案應轉換Nivolumab單藥維持</td>
      </tr>
      <tr>
        <td>"所有免疫治療劑量可互換"</td>
        <td>O+Y肝毒性與劑量直接相關<br />(CheckMate 040)</td>
        <td>嚴格遵循3mg/kg(N)+1mg/kg(I)標準</td>
      </tr>
    </table>

    <!-- 參考文獻 -->
    <div class="section-title">參考文獻</div>
    <div class="reference">
      <p>
        1. Overman MJ, et al.
        <a href="https://doi.org/10.1016/S1470-2045(17)30422-9" target="_blank"
          >Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite
          Instability-High Metastatic Colorectal Cancer</a
        >. J Clin Oncol. 2018;36(8):773-779. PMID: 29355075
      </p>

      <p>
        2. Marabelle A, et al.
        <a href="https://doi.org/10.1126/science.aan6733" target="_blank"
          >Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with
          pembrolizumab</a
        >. Science. 2020;367(6480):409-413. PMID: 31942094
      </p>

      <p>
        3. Yau T, et al.
        <a href="https://doi.org/10.1016/S1470-2045(20)30494-2" target="_blank"
          >Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma
          Previously Treated With Sorafenib</a
        >. Lancet Oncol. 2020;21(7):946-958. PMID: 32553139
      </p>

      <p>
        4. NCCN Clinical Practice Guidelines in Oncology:
        <a href="https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1454" target="_blank"
          >Colon Cancer Version 2.2025</a
        >. Accessed June 2025.
      </p>

      <p>
        5. Wang C, et al.
        <a href="https://doi.org/10.1038/s41591-019-0638-5" target="_blank"
          >B2M mutations mediate immune resistance in MSI-H metastatic colorectal cancer</a
        >. Nat Med. 2019;25(11):1695-1700. PMID: 31686035
      </p>
    </div>
  </body>
</html>
